Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRB037
MIFTS: 71

Cerebral Palsy

Categories: Eye diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cerebral Palsy

About this section

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 38 12 76 53 54 29 55 6 43 3 15 73
Infantile Cerebral Palsy 12 73
Cerebral Palsy, Mixed 73
Mixed Cerebral Palsy 53
Palsy, Cerebral 40
Palsy Cerebral 76

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1969
ICD10 33 G80 G80.9
MeSH 44 D002547
NCIt 50 C34460
SNOMED-CT 68 1178005
Sources

Summaries for Cerebral Palsy

About this section
NINDS : 54 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and inherited congenital spastic tetraplegia, and has symptoms including seizures, tremor and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Vesicle-mediated transport and Clathrin derived vesicle budding. The drugs Sevoflurane and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 53 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 43 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Sources

Related Diseases for Cerebral Palsy

About this section

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 444)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 34.2 F5 GAD1 PLP1
2 inherited congenital spastic tetraplegia 33.0 ADD3 GAD1 KANK1
3 hypertonia 32.4 AP4B1 AP4M1 AP4S1
4 spastic paraplegia 50, autosomal recessive 32.3 AP4B1 AP4M1 AP4S1
5 hereditary spastic paraplegia 32.0 AP4B1 AP4M1 ATL1 PLP1
6 hereditary spastic paraplegia 51 31.9 AP4B1 AP4S1
7 spastic paraplegia 2, x-linked 31.8 AP4B1 ATL1 PLP1
8 leukomalacia 30.5 IL6 TNF
9 chorioamnionitis 30.2 IL1B IL6 MMP8 TNF
10 eclampsia 30.1 F2 MTHFR TNF
11 placental abruption 30.0 F2 F5 MTHFR
12 thrombophilia 29.9 F2 F5 MTHFR
13 pre-eclampsia 29.8 F2 F5 IL6 MTHFR TNF
14 cytomegalovirus infection 29.8 IL1B IL6 TNF
15 stroke, ischemic 29.8 APOE F2 F5 MTHFR
16 arthritis 29.8 IL1B IL6 LTA TNF
17 pyelonephritis 29.6 IL1B IL6 TNF
18 porencephaly 29.6 COL4A1 F2 F5 MTHFR
19 gingivitis 29.6 IL1B IL6 MMP8 TNF
20 multiple sclerosis 29.6 APOE IL1B IL6 LTA PLP1 TNF
21 placenta disease 29.6 F5 IL1B IL6 MTHFR
22 periodontitis, chronic 29.6 IL1B IL6 MMP8
23 schizencephaly 29.6 COL4A1 F5 MTHFR
24 juvenile rheumatoid arthritis 29.5 IL1B IL6 LTA TNF
25 preterm premature rupture of the membranes 29.5 IL1B IL6 MMP8
26 periodontitis 29.4 IL1B IL6 MMP8 TNF
27 periodontal disease 29.4 IL1B IL6 MMP8 TNF
28 cerebral palsy, ataxic, autosomal recessive 12.8
29 dyskinetic cerebral palsy 12.7
30 spastic diplegia cerebral palsy 12.7
31 cerebral palsy, spastic quadriplegic, 1 12.5
32 mixed cerebral palsy 12.5
33 cerebral palsy, spastic quadriplegic, 2 12.5
34 cerebral palsy, spastic quadriplegic, 3 12.4
35 spastic quadriplegia 12.4
36 spastic hemiplegia 12.4
37 cerebral palsy athetoid 12.4
38 spastic diplegia 12.4
39 spastic monoplegia 12.1
40 intellectual disability - athetosis - microphthalmia 12.0
41 periventricular leukomalacia 11.6
42 spasticity 11.5
43 suprabulbar paresis, congenital 11.5
44 fetal methylmercury syndrome 11.5
45 swallowing disorders 11.5
46 spastic paraplegia 47, autosomal recessive 11.4
47 spastic paraplegia 52, autosomal recessive 11.4
48 dysphagia 11.4
49 athetosis 11.4
50 neonatal stroke 11.4

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy
Sources

Symptoms & Phenotypes for Cerebral Palsy

About this section

UMLS symptoms related to Cerebral Palsy:


seizures, tremor, dystonia, back pain, pain, abnormality of extrapyramidal motor function, involuntary movements, headache, torticollis, muscle fibrillation, syncope, athetosis, myokymia, chronic pain, sciatica, muscle rigidity, vertigo/dizziness, sleeplessness, asterixis

MGI Mouse Phenotypes related to Cerebral Palsy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.23 AP4B1 AP4E1 APOE ATL1 COL4A1 F2
2 homeostasis/metabolism MP:0005376 10.21 AP4E1 AP4M1 APOE COL4A1 F2 F5
3 growth/size/body region MP:0005378 10.18 AP4E1 APOE COL4A1 F2 F5 GAD1
4 cardiovascular system MP:0005385 10.13 ADD3 AP4E1 APOE COL4A1 F2 F5
5 nervous system MP:0003631 10.07 AP4B1 AP4E1 APOE COL4A1 F2 F5
6 limbs/digits/tail MP:0005371 9.87 AP4E1 APOE ATL1 GAD1 LTA MTHFR
7 respiratory system MP:0005388 9.7 APOE COL4A1 F2 GAD1 IL6 LTA
8 skeleton MP:0005390 9.65 AP4E1 APOE F2 GAD1 IL1B IL6
9 vision/eye MP:0005391 9.23 AP4E1 APOE COL4A1 IL6 LTA MTHFR
Sources

Drugs & Therapeutics for Cerebral Palsy

About this section

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-84-3 187
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7487-88-9 24083
7
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
8
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
9
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
10
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
11
Desipramine Approved, Investigational Phase 4 50-47-5 2995
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
14
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
15 Adrenergic alpha-Agonists Phase 4,Phase 1
16 Adrenergic Agonists Phase 4,Phase 2,Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
18 Adrenergic Agents Phase 4,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
20 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
21 Anesthetics, Inhalation Phase 4,Not Applicable
22 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
23 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Hypnotics and Sedatives Phase 4,Not Applicable
27 Anesthetics, General Phase 4,Not Applicable
28 Platelet Aggregation Inhibitors Phase 4,Not Applicable
29 Dopamine Agents Phase 4
30 Carbidopa, levodopa drug combination Phase 4
31 Sympathomimetics Phase 4,Phase 2
32 Dihydroxyphenylalanine Phase 4
33 Cardiotonic Agents Phase 4,Phase 2
34 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Acetylcholine Release Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
47 calcium channel blockers Phase 4,Phase 3,Phase 2,Not Applicable
48 Hematinics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113427-24-0
50 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 758)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
7 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
8 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
9 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
10 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
11 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
12 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Completed NCT03117322 Phase 4
13 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants Completed NCT01393496 Phase 4
16 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
17 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
18 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
19 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
20 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
21 Desipramine in Infantile Neuroaxonal Dystrophy (INAD). Enrolling by invitation NCT03726996 Phase 4 Desipramine
22 Paracetamol Study in Patients With Low Muscle Mass Not yet recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
23 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
24 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
25 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
26 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
27 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
28 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
29 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
30 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
31 Project:Intensive Habilitation (PIH) Unknown status NCT00202761 Phase 2, Phase 3
32 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
33 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
34 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
35 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
36 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
37 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
38 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Completed NCT01929434 Phase 3
39 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
40 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
41 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)
42 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
43 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
44 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
45 Efficacy of Intermittent Serial Casting on Spastic Wrist Flexion Deformity Completed NCT03306212 Phase 3 Botulinum toxin A
46 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
47 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
48 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
49 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
50 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cerebral Palsy:
Bone marrow-derived mononuclear cells for the treatment of cerebral palsy
Umbilical cord-derived mesenchymal stem cells for treatment of cerebral palsy
Embryonic/Adult Cultured Cells Related to Cerebral Palsy:
Umbilical cord-derived mesenchymal stem cells (family)
Sources

Genetic Tests for Cerebral Palsy

About this section

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29
Sources

Anatomical Context for Cerebral Palsy

About this section

MalaCards organs/tissues related to Cerebral Palsy:

41
Brain, Bone, Testes, Heart, Spinal Cord, Bone Marrow, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Cerebral Palsy

About this section

Articles related to Cerebral Palsy:

(show top 50) (show all 2808)
# Title Authors Year
1
Developmental Trajectories and Reference Percentiles for the 6-Minute Walk Test for Children With Cerebral Palsy. ( 30557281 )
2019
2
Commentary on "Developmental Trajectories and Reference Percentiles for the 6-Minute Walk Test for Children With Cerebral Palsy". ( 30557282 )
2019
3
Effects of a Gaming Platform on Balance Training for Children With Cerebral Palsy: Erratum. ( 30557292 )
2019
4
Comparison of simultaneous static standing balance data on a pressure mat and force plate in typical children and in children with cerebral palsy. ( 30308334 )
2019
5
Kinematic adaptation and changes in gait classification in running compared to walking in children with unilateral spastic cerebral palsy. ( 30312847 )
2019
6
Repeatability of electromyography recordings and muscle synergies during gait among children with cerebral palsy. ( 30396059 )
2019
7
Hand function in children with unilateral spastic cerebral palsy. ( 30256057 )
2019
8
The influence of crouch gait on sagittal trunk position and lower lumbar spinal loading in children with cerebral palsy. ( 30290367 )
2019
9
Mechanical work, kinematics, and kinetics during sit-to-stand in children with and without spastic diplegic cerebral palsy. ( 30292914 )
2019
10
Running in people with cerebral palsy: A systematic review. ( 29405796 )
2019
11
Clinician perspectives and experiences in the prescription of ankle-foot orthoses for children with cerebral palsy. ( 29465276 )
2019
12
Basic visual perceptual processes in children with typical development and cerebral palsy: The processing of surface, length, orientation, and position. ( 29498326 )
2019
13
The continually changing epidemiology of cerebral palsy. ( 29430775 )
2018
14
O 026 - Negative impact of muscle weakness and spasticity on gait in children with unilateral cerebral palsy. ( 29954655 )
2018
15
Management of hypertonia in cerebral palsy. ( 29135566 )
2018
16
Comparative study of home and community participation among children with and without cerebral palsy. ( 29957491 )
2018
17
Prevalence of sleep problems and sleep-related characteristics in preschool- and school-aged children with cerebral palsy. ( 29966807 )
2018
18
Medial gastrocnemius structure and gait kinetics in spastic cerebral palsy and typically developing children: A cross-sectional study. ( 29794756 )
2018
19
Dynamic spasticity determines hamstring length and knee flexion angle during gait in children with spastic cerebral palsy. ( 29960141 )
2018
20
Manual dexterity, but not cerebral palsy, predicts cognitive functioning after neonatal stroke. ( 29624666 )
2018
21
"Cerebral Palsy" in a Patient With Arginase Deficiency. ( 29961498 )
2018
22
Learning to cope with mirror movements in unilateral spastic cerebral palsy: a brief report. ( 29787338 )
2018
23
The natural history of crouch gait in bilateral cerebral palsy: A systematic review. ( 29960128 )
2018
24
Clinical characteristics and functional status of children with different subtypes of dyskinetic cerebral palsy. ( 29794768 )
2018
25
Bike skills training for children with cerebral palsy: protocol for a randomised controlled trial. ( 29431140 )
2018
26
Dorsal rhizotomy for children with spastic diplegia of cerebral palsy origin: usefulness of intraoperative monitoring. ( 29652243 )
2018
27
Validation of reaching in a virtual environment in typically developing children and children with mild unilateral cerebral palsy. ( 29427357 )
2018
28
Trunk control and functionality in children with spastic cerebral palsy. ( 29652201 )
2018
29
Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. ( 29694645 )
2018
30
Contribution of perinatal conditions to cerebral palsy in Uganda. ( 29433660 )
2018
31
Muscle morphology of the lower leg in ambulant children with spastic cerebral palsy. ( 29981242 )
2018
32
Surgical reconstruction of hip subluxation and dislocation in children with cerebral palsy. ( 29526153 )
2018
33
Age trajectories of musculoskeletal morbidities in adults with cerebral palsy. ( 29981509 )
2018
34
Slip avoidance strategies in children with bilateral spastic cerebral palsy and crouch gait. ( 29679933 )
2018
35
<i>TSEN54</i> Gene-Related Pontocerebellar Hypoplasia Type 2 Could Mimic Dyskinetic Cerebral Palsy with Severe Psychomotor Retardation. ( 29410950 )
2018
36
Identification of a candidate enhancer for DMRT3 involved in spastic cerebral palsy pathogenesis. ( 29305858 )
2018
37
Functional capacity in adults with cerebral palsy: Lower limb muscle strength matters. ( 29438658 )
2018
38
Development of postural control in infancy in cerebral palsy and cystic periventricular leukomalacia. ( 29787891 )
2018
39
Virtual reality training for children with unilateral cerebral palsy. ( 29442357 )
2018
40
The Relationship Between Hand Function and Overlapping Motor Representations of the Hands in the Contralesional Hemisphere in Unilateral Spastic Cerebral Palsy. ( 29303031 )
2018
41
Re-engineering the interpretation of electronic fetal monitoring to identify reversible risk for cerebral palsy: a case control series. ( 29447043 )
2018
42
Relationship between radiographic patella-alta pathology and walking dysfunction in children with bilateral spastic Cerebral Palsy. ( 29149666 )
2018
43
An Unreported Cause of Intrathecal Baclofen Withdrawal Symptoms in a Woman With Spastic Cerebral Palsy Who Received Intrathecal Gablofen. ( 29521737 )
2018
44
O 023 - Crouch gait in children with Cerebral Palsy and the impact on trunk kinematics and lower lumbar spinal loading. ( 29980441 )
2018
45
Path analysis of strength, spasticity, gross motor function, and health-related quality of life in children with spastic cerebral palsy. ( 29673348 )
2018
46
Estimating medial gastrocnemius muscle volume in children with spastic cerebral palsy: a cross-sectional investigation. ( 29067675 )
2018
47
Determine the Relationship Between Abdominal Muscle Strength, Trunk Control and Urinary Incontinence in Children with Diplegic Cerebral Palsy. ( 29427287 )
2018
48
Needs for Medical and Rehabilitation Services in Adults With Cerebral Palsy in Korea. ( 29961745 )
2018
49
Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. ( 29405267 )
2018
50
Casting Protocols Following BoNT-A Injections to Treat Spastic Hypertonia of the Triceps Surae in Children with Cerebral Palsy and Equinus Gait: A Randomized Controlled Trial. ( 29771161 )
2018
Sources

Variations for Cerebral Palsy

About this section

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007
2 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh38 Chromosome 10, 110122249: 110122249
Sources

Expression for Cerebral Palsy

About this section
Search GEO for disease gene expression data for Cerebral Palsy.
Sources

Pathways for Cerebral Palsy

About this section

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Vesicle-mediated transport 66
Show member pathways
 13.28 AP4B1 AP4E1 AP4M1 AP4S1 APOE COL4A1
2
Clathrin derived vesicle budding 66
Show member pathways
 12.31 AP4B1 AP4E1 AP4M1 AP4S1
3
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.07 IL1B IL6 PLP1 TNF
4
Th1 Differentiation Pathway 65
Show member pathways
 11.96 IL1B IL6 LTA TNF
5
Lysosome 37
11.9 AP4B1 AP4E1 AP4M1 AP4S1
6
Spinal Cord Injury 1
11.86 COL4A1 IL1B IL6 TNF
7
Hematopoietic cell lineage 37
11.82 IL1B IL6 TNF
8
NF-kappa B signaling pathway 37
11.8 IL1B LTA TNF
9
TNF signaling pathway 37
11.78 IL1B IL6 LTA TNF
10
Rheumatoid arthritis 37
11.77 IL1B IL6 TNF
11
Selenium Micronutrient Network 1
Show member pathways
 11.77 APOE F2 IL1B IL6 MTHFR TNF
12
Innate Lymphoid Cell Differentiation Pathways 65
11.72 IL1B LTA TNF
13
AGE-RAGE signaling pathway in diabetic complications 37
11.7 COL4A1 IL1B IL6 TNF
14
Pertussis 37
11.68 IL1B IL6 TNF
15
Dendritic Cells Developmental Lineage Pathway 65
11.66 IL1B IL6 TNF
16
Amoebiasis 37
11.65 COL4A1 IL1B IL6 TNF
17
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.65 COL4A1 F2 IL1B IL6 TNF
18
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.64 IL1B IL6 TNF
19
Lung fibrosis 1
11.58 IL1B IL6 TNF
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 IL1B IL6 TNF
21
Legionellosis 37
11.5 IL1B IL6 TNF
22
Interleukin-10 signaling 66
11.44 IL1B IL6 TNF
23
Malaria 37
11.43 IL1B IL6 TNF
24
African trypanosomiasis 37
11.26 IL1B IL6 TNF
25
IL-10 Pathway 64
11.24 IL1B IL6 TNF
26
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.21 APOE IL1B IL6 TNF
27
Development and heterogeneity of the ILC family 1
11.18 IL1B IL6 TNF
28
G-protein signaling_RhoB regulation pathway 22
11.12 IL1B IL6 LTA TNF
29
Cytokines and Inflammatory Response 1
11.1 IL1B IL6 TNF
30
G-protein signaling_Rap2B regulation pathway 22
10.95 COL4A1 IL1B IL6 LTA TNF
31
Overview of nanoparticle effects 1
10.78 COL4A1 IL6 TNF
32
Antifolate resistance 37
10.42 IL1B IL6 MTHFR TNF
Sources

GO Terms for Cerebral Palsy

About this section

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 APOE COL4A1 F2 F5 IL1B IL6
2 endoplasmic reticulum lumen GO:0005788 9.65 APOE COL4A1 F2 F5 IL6
3 trans-Golgi network membrane GO:0032588 9.46 AP4B1 AP4E1 AP4M1 AP4S1
4 endosome lumen GO:0031904 9.26 AP4B1 AP4E1 AP4M1 AP4S1
5 AP-4 adaptor complex GO:0030124 8.92 AP4B1 AP4E1 AP4M1 AP4S1
6 extracellular region GO:0005576 10.02 APOE COL4A1 F2 F5 IL1B IL6

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 IL1B IL6 MMP8 PLP1 TNF
2 cellular protein metabolic process GO:0044267 9.92 APOE F2 F5 IL6
3 defense response to Gram-positive bacterium GO:0050830 9.82 IL6 LTA TNF
4 positive regulation of JNK cascade GO:0046330 9.81 IL1B MMP8 TNF
5 response to glucocorticoid GO:0051384 9.78 IL1B IL6 TNF
6 humoral immune response GO:0006959 9.75 IL6 LTA TNF
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 IL1B MMP8 TNF
8 positive regulation of interferon-gamma production GO:0032729 9.71 IL1B LTA TNF
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 IL1B MMP8 TNF
10 protein localization GO:0008104 9.67 AP4B1 AP4E1 AP4M1 AP4S1
11 negative regulation of growth of symbiont in host GO:0044130 9.65 LTA TNF
12 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL1B TNF
13 locomotory exploration behavior GO:0035641 9.64 APOE GAD1
14 negative regulation of lipid storage GO:0010888 9.63 IL6 TNF
15 negative regulation of platelet activation GO:0010544 9.62 APOE F2
16 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL1B TNF
17 regulation of establishment of endothelial barrier GO:1903140 9.58 IL1B TNF
18 negative regulation of neurogenesis GO:0050768 9.58 IL1B IL6 TNF
19 positive regulation of fever generation GO:0031622 9.56 IL1B TNF
20 positive regulation of interleukin-6 production GO:0032755 9.56 IL1B IL6 MMP8 TNF
21 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.55 LTA TNF
22 chronic inflammatory response to antigenic stimulus GO:0002439 9.51 IL1B TNF
23 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.5 APOE IL1B TNF
24 sequestering of triglyceride GO:0030730 9.49 IL1B TNF
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IL1B TNF
26 regulation of microglial cell activation GO:1903978 9.46 MMP8 TNF
27 protein targeting GO:0006605 9.46 AP4B1 AP4E1 AP4M1 AP4S1
28 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.43 LTA TNF
29 positive regulation of glial cell proliferation GO:0060252 9.26 IL1B IL6 LTA TNF
30 positive regulation of neuroinflammatory response GO:0150078 8.92 IL1B IL6 MMP8 TNF
31 regulation of signaling receptor activity GO:0010469 10.01 F2 IL1B IL6 LTA TNF

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL1B IL6 LTA TNF
Sources

Sources for Cerebral Palsy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....